The recent acquisition of Relief Therapeutics by Sonnet BioTherapeutics will surely fuel the growth of Chemotherapy-Induced Peripheral Neuropathy (CIPN) therapy market. Sonnet plans to commence the development of its promising candidate SON-080 for CIPN treatment.
Peripheral Neuropathy is a set of complications caused as a result of damage to the distant nerves away from the brain and spinal cord. Cancer patients undergoing chemotherapy usually suffer from CIPN. Chemotherapy along with other drugs are potentials caused by the damage to the distant nerves in the Cancer patients. This is one of the disabling side effects of cancer treatment. CIPN can hamper routine activities like the ability to walk, write, bend, and even as easy as picking up a coin, along with severing body pain. The more severe form of CIPN can affect heart rate, blood pressure, and even paralysis and organ failure.
Chemotherapy-Induced Peripheral Neuropathy Epidemiology
According to DelveInsight, the CIPN incident population assessed in G8 countries is expected to increase at a CAGR of 0.35% in the study period of 2016-27. Moreover, a higher CIPN incidence was observed in China with 1,542,149 cases in 2016, owing to the fact that China has relatively higher cancer cases as compares to other countries in 7MM. Among EU countries, Germany had the highest CIPN prevalence, followed by the UK, with Spain having the lowest CIPN prevalence.
Studies reveal that majority of the CIPN cases is caused by the platinum-based chemotherapeutic agents such as oxaliplatin and cisplatin, followed by taxane agents. Also, in terms of severity, the majority of the patients have been diagnosed with moderate and severe forms of CIPN, while a slightly lesser number of mild CIPN were diagnosed. In 2016, mild, moderate and severe CIPN incidence in the US varied in the range 100,000 to 300,000. This trend is expected to be followed during the forecast period [2018-2027].
Chemotherapy-Induced Peripheral Neuropathy Therapy Market
The CIPN therapy market size depends entirely on the type of nerve damage, symptoms, and location. Currently, there is no approved therapy for the treatment of CIPN. The current CIPN therapeutic landscape worldwide is dependent on off-label therapies, used to reduce the symptoms in CIPN patients. There is no agent that has demonstrated efficacy in the prevention of CIPN, despite the evaluation of many therapies traditionally used in the treatment of neuropathic pain.
Among the different classes of therapies which are currently prescribed to CIPN patients, opioid analgesics are the most prescribed one that led to highest CIPN market size among other classes.
Opioids, which occupy the maximum market share in CIPN market, include codeine, fentanyl, morphine, tapentadol, tramadol and others. Followed by Opioids, Alpha-2-delta antagonist (Anticonvulsants), including gabapentin and pregabalin, are frequently prescribed for neuropathic pain and occupy the second-highest CIPN market share.
Chemotherapy-Induced Peripheral Neuropathy Market Landscape
The overall CIPN market trend will be positive owing to the expected launch of emerging therapies. The CIPN market size of currently available off-label therapies is expected to experience steady growth until a standard effective CIPN-dedicated therapy develops. The CIPN market of off-label
therapies might further slow-down post the launch of targeted therapies. Due to the unmet needs in the field of CIPN, many promising candidates in the late stage of clinical development for the treatment of CIPN which are expected to create an impact on the CIPN market during the forecast period. Companies are aggressively working towards the development of targeted CIPN therapies such as PledOx/Solasia, WEX Pharmaceuticals, Asahi Kasei, MediciNova, Achelios Therapeutics, Esteve, ChromaDex, Apollo endosurgery (Lpath), Hoffmann-La Roche, Midatech/DARA, Lee's Pharmaceutical Limited, Novartis, Relief Therapeutics and others.
The Chemotherapy-Induced Peripheral Neuropathy market size in the G8 Countries is expected to increase at a CAGR of 2.94% for the study period. China accounts for the highest market size of CIPN in comparison to the United States, the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. Expected launch of potential CIPN therapies may increase the market size in the coming years, assisted by an increase in the CIPN incident population. Overall, the increasing incidence, awareness of the disease and promising emerging pipeline therapies will substantially fuel the market size during the forecast period of 2018-2027.